Cancer Vaccines

Cyclacel Receives Patent On Drug Target Of Cancer Cell Cycle

Published in Cancer Weekly, November 27th, 2001

Cyclacel, Ltd., has been granted United States Patent 6,242,201 covering the cancer drug target PCNA (proliferating cell nuclear antigen).

Cyclacel's CYC102 program is seeking to prevent cancer cell proliferation through drugs acting on PCNA. The CYC102 studies are based on the understanding that inhibition of PCNA prevents DNA replication, a prerequisite to cancer cell division. Cyclacel is working on this target because it is associated with the body's own tumour suppression systems, such as the p21 protein that prevents cancer cell division by inhibiting PCNA.

Cyclacel's new U.S. patent specifically covers both substances that mimic the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry